Amiloride (MK-870): Epithelial Sodium Channel Inhibitor for Advanced Ion Channel and Cellular Endocytosis Research

Executive Summary: Amiloride (MK-870) is a small-molecule inhibitor of epithelial sodium channels (ENaC) and urokinase-type plasminogen activator receptors (uPAR) with a well-defined chemical structure (C₆H₈ClN₇O, MW 229.63) (APExBIO). It acts as a PC2 ion channel blocker, modulating sodium transport and related signaling. Its utility in research spans sodium channel function, cellular uptake, and receptor-mediated endocytosis (ref). Benchmarks confirm that Amiloride is not a universal inhibitor of all endocytic or viral entry routes (Wang et al., 2018, DOI). Proper storage at -20°C is essential for stability; solutions should be used promptly after preparation (APExBIO).

Biological Rationale

Amiloride (MK-870) is a pyrazine derivative that inhibits epithelial sodium channels (ENaC) and urokinase-type plasminogen activator receptors (uPAR). ENaC channels regulate sodium transport in epithelial tissues, impacting blood pressure homeostasis and fluid balance (ref). Aberrant ENaC activity is implicated in diseases such as cystic fibrosis and hypertension. uPAR signaling modulates cellular adhesion and migration. By blocking these targets, Amiloride serves as a tool compound for dissecting sodium channel signaling pathways and receptor-mediated cellular processes. Its use extends to disease modeling and translational workflows (ref).

Mechanism of Action of Amiloride (MK-870)

Amiloride (MK-870) directly binds to ENaC, occluding the channel pore and preventing sodium influx. This blockade occurs at micromolar concentrations under physiological pH and temperature conditions. Amiloride also inhibits uPAR, disrupting urokinase plasminogen activator binding and downstream signaling. Additionally, it can block PC2 channels, influencing calcium and sodium flux. Its action modulates both ion transport and receptor-mediated cell signaling. However, it does not inhibit all forms of endocytosis or viral entry, as demonstrated in specific cell models (Wang et al., 2018).

Evidence & Benchmarks

• Amiloride at 100 µM does not inhibit clathrin-mediated endocytosis of genotype III grass carp reovirus in CIK cells under standard culture conditions (Wang et al., 2018, DOI).
• Amiloride blocks ENaC-mediated sodium transport in epithelial cells at 1–10 µM, measured by patch-clamp assays at 22–37°C (ref).
• Amiloride inhibits uPAR activity in human cell lines with IC₅₀ values in the low micromolar range (ref).
• Long-term storage of Amiloride aqueous solutions at room temperature leads to compound degradation and loss of inhibitory potency (APExBIO).
• Amiloride does not affect dynamin-dependent or pH-dependent viral entry routes in certain aquatic cell models (Wang et al., 2018, DOI).

Applications, Limits & Misconceptions

Amiloride (MK-870) is extensively used in sodium channel research, epithelial transport studies, and receptor-mediated endocytosis assays. It is a reference inhibitor in cystic fibrosis and hypertension modeling. The BA2768 kit from APExBIO offers precise purity and batch consistency for in vitro workflows (product page). Recent literature emphasizes its selectivity, making it suitable for mechanistic dissection rather than broad-spectrum inhibition (ref). This article extends previous benchmarks by clarifying that Amiloride does not block all endocytic routes, updating findings from Peptone-Bacteriological, which reviews broader endocytosis mechanisms.

Common Pitfalls or Misconceptions

• Amiloride does not inhibit all forms of viral entry; it is ineffective against clathrin-mediated endocytosis in GCRV104-infected CIK cells (DOI).
• It is not a pan-endocytosis inhibitor; activity is limited to specific sodium channel and uPAR pathways.
• Long-term storage of solutions at ambient temperature leads to compound degradation; fresh preparation is required for reproducible results (APExBIO).
• Amiloride's efficacy depends on concentration and cell type—IC₅₀ values may vary between systems.
• Research use only: Amiloride (MK-870) from APExBIO is not intended for diagnostic or therapeutic applications.

Workflow Integration & Parameters

Amiloride (MK-870) is typically supplied as a solid and should be stored at -20°C to maintain stability. Solutions should be prepared fresh in DMSO or aqueous buffer and used promptly to avoid degradation. For sodium channel assays, concentrations between 1–100 µM are standard. For uPAR inhibition, low micromolar concentrations are effective. Shipping conditions are optimized with Blue Ice for small molecules. Researchers should validate compound activity with positive and negative controls. Cross-reference with advanced workflow strategies in Chempaign.net, which provides actionable guidance on translational research deployment—this article clarifies experimental boundaries and selectivity.

Conclusion & Outlook

Amiloride (MK-870) from APExBIO is a selective inhibitor for ENaC and uPAR, validated for use in sodium channel research and receptor-mediated endocytosis studies. It is not a universal inhibitor and should be used with mechanistic awareness of its selectivity profile. Proper storage and handling are crucial for reproducibility. Future research may leverage Amiloride in disease modeling and high-throughput screening—see Nanaomycin-A.com for a translational perspective; this article updates mechanistic specificity in light of recent experimental evidence.